AclarionNASDAQ: ACON

Established in 1932, the London Clinic is the UK's Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract Extension Aligns Aclarion and The London Clinic With Engaging Payers to Increase Access to Nociscan for Both Patients and Referring Physicians BROOMFIELD, CO, June 25, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today they are extending their commercial agreement with the prestigious London Clinic in London, UK. The contract extension establishes a higher price point for Nociscan, engages The London Clinic to secure payer coverage decisions from leading private health insurers, and aligns Aclarion with The London Clinic in expanding access to referring physicians throughout the greater London market.

Aclarion (NASDAQ: ACON ) stock is falling on Monday after the healthcare technology company revealed plans for a public offering of its shares. Aclarion intends to offer up to 3,888,888 units in this offering.

Aclarion (NASDAQ: ACON ) stock is falling on Monday after the healthcare technology company announced additional exchange agreements with accredited investors. According to a filing with the Securities and Exchange Commission (SEC), Aclarion issued 500,000 shares of ACON stock in exchange for $1,185,226 of principal and accrued interest on unsecured non-convertible notes.

Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Aclarion shares skyrocketed after the company published data from a two-year trial that demonstrated improved surgical outcomes for discogenic lower back pain (DLBP) surgeries at chemically painful lumbar discs identified by Nociscan, the company's intelligence platform for measuring pain biomarkers in the lumbar spine. Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine and uses its proprietary signal processing techniques to extract and quantify chemical biomarkers associated with disc pain, according to Aclarion.